Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Webinars
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Gastroenterology
  • Gastroenterology News
  • GLP-1 Receptor...

GLP-1 Receptor Agonists Show Gastrointestinal Safety with Some Risks: Study

Written By : Medha Baranwal |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2025-10-04T08:00:52+05:30  |  Updated On 4 Oct 2025 11:54 AM IST
GLP-1 Receptor Agonists Show Gastrointestinal Safety with Some Risks: Study
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

USA: Researchers have found in a retrospective study that GLP-1 receptor agonists (RAs) are generally safe for the gastrointestinal (GI) and hepatobiliary systems in patients with type 2 diabetes (T2D).

The study published in the American Journal of Gastroenterology revealed that the therapy was linked to lower risks of several GI cancers and complications compared with other oral antidiabetic drugs. However, GLP-1 RAs were associated with a higher risk of
gastroparesis
and intussusception, highlighting the need for careful monitoring in vulnerable patients.
The study, led by Dr. Chengu Niu from the Department of Internal Medicine, Rochester General Hospital, USA, analyzed electronic health records of adults with T2D treated across the United States between 2010 and 2020. Using data from the TriNetX network, researchers conducted a retrospective cohort analysis and included 230,415 patients receiving GLP-1 RAs, matched 1:1 with an equal number of patients on other oral antidiabetic medications such as metformin, empagliflozin, and sitagliptin.
Over a five-year follow-up, the study evaluated various GI and hepatobiliary outcomes, including gastroparesis, bowel obstruction, pancreatitis, cholecystitis, and related GI cancers.
The analysis revealed the following findings:
  • GLP-1 RA use was associated with a higher risk of gastroparesis (HR 1.591).
  • GLP-1 RA use was associated with a higher risk of intussusception (HR 1.383).
  • GLP-1 RA therapy was linked to 15%–26% lower risks of cholangitis, bowel obstruction, ileus, volvulus, chronic pancreatitis, and procedures such as endoscopic retrograde cholangiopancreatography compared to other oral antidiabetic drugs.
  • GLP-1 RA users had lower risks of pancreatic cancer (HR 0.897), gastric cancer (HR 0.838), esophageal cancer (HR 0.741), and colorectal cancer (HR 0.870).
  • There were no significant differences in the risk of biliary cancer or hepatocellular carcinoma between GLP-1 RA users and other oral antidiabetic drug users.
  • Rates of acute pancreatitis, cholecystitis, and cholecystectomy were similar between GLP-1 RA users and the control group.
  • Overall, these findings support the gastrointestinal and hepatobiliary safety of GLP-1 receptor agonists.
The findings suggest that for patients at risk of common GI malignancies or conditions such as cholangitis and bowel obstruction, GLP-1 RAs remain a viable and generally safe option. However, clinicians are advised to exercise caution in patients with preexisting gastroparesis or intussusception, who may benefit from traditional oral antidiabetic therapies instead.
The authors noted several limitations of the study. The results show associations rather than causation, and the five-year follow-up period may not fully capture long-term cancer risks. Socioeconomic factors, access to healthcare, treatment adherence, and medication switching were not assessed and could have influenced outcomes.
"The large real-world analysis supports the gastrointestinal and hepatobiliary safety of GLP-1 receptor agonists in patients with type 2 diabetes, while highlighting the need for vigilance regarding specific complications such as gastroparesis and intussusception. Further long-term studies are needed to confirm these findings and to better assess potential cancer risks associated with GLP-1 RA therapy," the authors concluded.
Reference:
Niu, Chengu MD1,a; Sun, Kefang MD1; Zhang, Jing MD2; Elkhapery, Ahmed MD1; Zhu, Kaiwen MD1; Malik, Sheza MD1; Xue, Chao MD1; Okolo, Patrick I MD3. Gastrointestinal and Hepatobiliary Safety of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes. The American Journal of Gastroenterology ():10.14309/ajg.0000000000003760, September 03, 2025. | DOI: 10.14309/ajg.0000000000003760


American Journal of Gastroenterologyglucagon-like peptide-1 receptor agonists (GLP-1 RAs)type 2 diabetes mellitus (T2DM)
Source : American Journal of Gastroenterology
Medha Baranwal
Medha Baranwal

    MSc. Biotechnology

    Dr. Kamal Kant Kohli
    Dr. Kamal Kant Kohli

    Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial

    Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial

    Pneumococcal Vaccination in Hematological Malignancies (HM)-Indian Hematology Expert Consensus 2025

    Pneumococcal Vaccination in Hematological Malignancies (HM)-Indian Hematology Expert Consensus 2025

    Negligence vs Misconduct: Where Do Medical Councils Draw the Line?

    Negligence vs Misconduct: Where Do Medical Councils Draw the Line?

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    Real-World Case Insight: Triple FDC Therapy in a Young Diabetes Patient - Dr Naresh Kumar

    Pneumococcal Disease Risk and Vaccination in Cardiac Conditions: Indian Cardiologists Group Recommendations

    Pneumococcal Disease Risk and Vaccination in Cardiac Conditions: Indian Cardiologists' Group...

    View All

    Journal Club Today

    Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial

    Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial

    View All

    Health News Today

    Health Bulletin 03/October/2025

    Health Bulletin 03/October/2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok